Acuta Capital Partners’s Evolent Health EVH Stock Holding History

Acuta Capital Partners’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-420,000	Closed	-$5.17M	–	70
2017 Q4	$5.17M	Sell	420,000 -30,000	-7%	-$423K	0.98%	18
2017 Q3	$8.01M	Buy	450,000 +169,400	+60%	+$3.49M	1.44%	17
2017 Q2	$7.11M	Buy	280,600 +130,600	+87%	+$3.14M	1.99%	13
2017 Q1	$3.35M	Buy	+150,000	New	+$2.88M	0.79%	32

Other funds holding EVH

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return

Acuta Capital Partners's EVH Position: Q1 2018 in Review

Acuta Capital Partners sold out of Evolent Health (EVH) in Q1 2018, closing a stake of 420,000 shares — an estimated $5.17M sold.

Acuta Capital Partners first reported a position in EVH in Q1 2017 and held it in 4 quarters. The position peaked at $8.01M in Q3 2017. 152 funds tracked by Wall St. Rank hold EVH as of Q1 2018.

Acuta Capital Partners reported no remaining Evolent Health position as of Q1 2018 after selling out during the quarter.
Acuta Capital Partners sold 420,000 Evolent Health shares in Q1 2018, an estimated $5.17M.
Acuta Capital Partners first reported a position in Evolent Health in Q1 2017 and held it in 4 quarters.
Acuta Capital Partners's Evolent Health position peaked at $8.01M in Q3 2017.
152 funds tracked by Wall St. Rank held Evolent Health as of Q1 2018.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.